logo
How Fast Is Too Fast to See? Study Reveals Your Visual Speed Limit

How Fast Is Too Fast to See? Study Reveals Your Visual Speed Limit

Gizmodo12-05-2025

When a camera whips around from one point to another, most people expect the fast movement to result in a blurry smear. What they don't realize, however, is that our own eyes engage in a similar kind of rapid movement—called saccades—over 100,000 times a day. Unlike video cameras, our brain avoids the nauseating blur—but when things move in a particular way, they become invisible.
As detailed in a study published May 8 in Nature Communications, researchers have revealed that the speed of an individual's saccades corresponds to the limit at which a moving object becomes too fast for them to see. That means people with faster eye movements can perceive faster-moving objects, with potential implications for activities requiring fast eye movements such as sports, video games, and even photography. The researchers claim to be the first to provide evidence for the theory that a person's movement impacts their perception.
'What parts of the physical world we can sense depends fundamentally on how good our sensors are,' Martin Rolfs, lead author of the study and an active vision scientist at Humboldt University of Berlin's Department of Psychology, said in a statement by the research group Science of Intelligence. 'In this paper, however, we show that the limits of seeing are not just defined by these biophysical constraints but also by the actions and movements that impose changes on the sensory system.'
Rolfs and his colleagues demonstrated that when a study participant saw visual stimuli moving with the same speed and pattern as their own saccade shifts, the stimuli became invisible. This suggests the brain filters out motion that mimics our own eye movements, which might be why our saccades don't cause visual blurs in the way that cameras do. More broadly, this suggests that physical movement—such as eye movement—limits our sensory system's perception of the world. In other words, our ability to see things in motion is not just dictated by our sensory abilities, such as the strength, or sensitivity, of the photoreceptors in our eyes.
'In simple terms, the properties of a sensory system such as the human visual system are best understood in the context of the kinematics of actions that drive its input (in this case, rapid eye movements),' said Rolfs. Kinematics is the study of object motion without considering the cause of said motion. 'Our visual system and motor system are finely tuned to each other, but this has long been ignored,' he continued. 'One of the issues is that the people who study motor control are not the same ones who study perception. They attend different conferences, they publish in different journals—but they should be talking!'
It's only a matter of time until helicopter parents start timing their kids' saccades to decide whether they belong in little league or theater.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025
Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025

Yahoo

time4 hours ago

  • Yahoo

Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025

Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025 Halle (Saale) / Munich, Germany, June 6, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that meta-analysis data for its lead drug in development, varoglutamstat, was presented at the 62nd ERA Congress of the European Renal Association in Vienna, Austria, today, June 6, 2025. 'We are delighted that the results of the Phase 2 program were accepted for presentation at the ERA 2025 congress. This allowed Vivoryon to share the outstanding improvements of varoglutamstat on kidney function (eGFR) with the scientific and medical expert community in the kidney space,' said Frank Weber, MD, CEO of Vivoryon. Presentation HighlightsVaroglutamstat is a first-in-class glutaminyl cyclase (QPCT/L) inhibitor with potent anti-inflammatory and anti-fibrotic effects. VIVIAD and VIVA-MIND, two independent Phase 2 studies in the EU and U.S. showed a statistically significant and clinically meaningful improvement in a prospectively defined kidney function parameter, eGFR, in an elderly patient population. This improvement was consistent in both trials independently, replicated in the meta-analysis and pooled analysis, and provides converging evidence for this finding. Statistically significant differences between varoglutamstat and placebo were first observed at week 24 and were sustained until week 96. The meta-analysis also confirmed a substantially larger effect size in study participants with diabetes compared to those without diabetes. The next step is planned to be a dedicated Phase 2b trial in patients with diabetic kidney disease (patients with diabetes and chronic kidney disease stage 3b/4). The main goal will be to investigate the efficacy on eGFR in this patient population and to obtain additional information on a potential effect on proteinuria and other kidney specific markers. Presentation Details Date: June 6, 2025Presentation time: 8:15 am CEST as part of the focused oral sessionTitle: Varoglutamstat improves eGFR and offers a new approach to treat diabetic kidney disease (DKD): meta-analysis from two independent Phase 2 studiesVenue: Vienna, Austria Presenter: Frank Weber, MD, CEO of Vivoryon Therapeutics ### About Vivoryon Therapeutics is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon's most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the 'Company'), estimates and projections with respect to the market for the Company's products and forecasts and statements as to when the Company's products may be available. Words such as 'anticipate,' 'believe,' 'estimate,' 'expect,' 'forecast,' 'intend,' 'may,' 'plan,' 'project,' 'predict,' 'should' and 'will' and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management's current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company's results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company's future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law. For more information, please contact: Investor ContactsVivoryon Therapeutics Manuela Bader, Director IR & CommunicationEmail: IR@ LifeSci AdvisorsSandya von der Weid Tel: +41 78 680 05 38Email: svonderweid@ Media ContactTrophic CommunicationsValeria Fisher or Verena SchossmannTel: +49 175 8041816 / +49 151 219 412 77Email: vivoryon@ Attachment 20250606_ERA_VVYSign in to access your portfolio

Dog Exposure Affects Genetic Risk in Eczema, Study Finds
Dog Exposure Affects Genetic Risk in Eczema, Study Finds

Medscape

time6 hours ago

  • Medscape

Dog Exposure Affects Genetic Risk in Eczema, Study Finds

Children with a genetic variant linked to atopic eczema (rs10214237) appeared less likely to develop the condition if they were exposed to dogs in their early years, according to a large European study. METHODOLOGY: Researchers analyzed 16 European cohorts (n = 25,339) and replicated findings in 10 more (n = 254,532). They tested for an interaction between 24 atopic eczema-associated genetic loci and 18 early-life environmental exposures. In vitro experiments assessed IL-7R expression in keratinocytes of known rs10214237 genotype after exposure to dog allergen using cells from multiple donors. TAKEAWAY: The discovery analysis revealed 14 significant interactions ( P < .05 for all) between at least one gene variant for eczema and seven environmental factors (antibiotic use, cat ownership, dog ownership, breastfeeding, elder sibling, smoking, and washing practices). < .05 for all) between at least one gene variant for eczema and seven environmental factors (antibiotic use, cat ownership, dog ownership, breastfeeding, elder sibling, smoking, and washing practices). The interaction between dog exposure and rs10214237 was confirmed in the replication analysis (odds ratio [OR], 0.91; P = .025). = .025). The T allele of rs10214237 increased the risk for atopic eczema only in individuals not exposed to dogs (OR, 1.14; 95% CI, 1.08-1.22) but not in those with dog exposure (OR, 0.99; 95% CI, 0.93-1.05). Keratinocytes with the T:T genotype demonstrated higher IL-7R mRNA expression than those with the C:C genotype. mRNA expression than those with the C:C genotype. Dog allergen exposure downregulated IL-33 and TSLP but upregulated CXCL8 , CSF2 , CCL2 , and TNF , suggesting enhanced IL-10 signaling, which plays a suppressive role in atopic eczema. IN PRACTICE: 'We know that genetic make-up affects a child's risk of developing eczema and previous studies have shown that owning a pet dog may be protective, but this is the first study to show how this may occur at a molecular level,' study author Sara J. Brown, MD, PhD, of the Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, Scotland, said in a press release from Wiley, the publisher of Allergy . 'More work is needed, but our findings mean we have a chance to intervene in the rise of allergic disease, to protect future generations.' SOURCE: The study was led by Marie Standl, Institute of Epidemiology, Helmholtz Zentrum München — German Research Center for Environmental Health, Neuherberg, Germany, and was published online on June 4 in Allergy . LIMITATIONS: Genome-wide interaction analysis was not conducted. Replication samples sizes were not powered for some interactions. Detailed data on environmental factors were not available. The inclusion of predominantly White population may limit generalizability of findings. DISCLOSURES: The study received funding from the Innovative Medicines Initiative 2 Joint Undertaking, which was supported by the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations. Many authors reported receiving research funding, honoraria, grants, and compensations for lectures and consulting from various organizations and pharmaceutical companies, including Wellcome Trust, UK Research and Innovation, Medical Research Council, Unilever, Pfizer, and AbbVie.

Europe will have to be more Tenacious to land its first rover on the Moon
Europe will have to be more Tenacious to land its first rover on the Moon

TechCrunch

time14 hours ago

  • TechCrunch

Europe will have to be more Tenacious to land its first rover on the Moon

Europe likely just suffered a setback in its attempt to reach another milestone in the commercial race to use lunar resources. Tenacious, which was set to become the first European-made rover to land on the Moon, was aboard a lander that lost contact during its landing attempt — a strong sign that something went wrong. If confirmed, this would be the second failed mission of the HAKUTO-R commercial lunar exploration program, two years after a previous crash that had already shattered hopes. This loss will be particularly felt in Japan; ispace, the company behind HAKUTO-R and the currently missing Resilience lander that carried Tenacious, is a publicly listed Japanese company. But it is also a blow to Europe: The European Space Agency (ESA) supported the mission; and the rover was designed, assembled, tested, and manufactured by ispace-EUROPE out of Luxembourg. Luxembourg isn't just ispace-EUROPE's base — it's the reason the entity was created in 2017. As part of its initiative, the tiny country became the second in the world after the U.S. to adopt a law giving companies the right to own resources extracted from space. Had Tenacious' Luxembourg-based operators managed to drive it around on the Moon, the rover would have captured video and gathered data. One of its missions would have been to collect lunar soil, called regolith, as part of a contract with NASA, to which it was supposed to transfer ownership of the samples. 'I think this will be very helpful to nail down what it means to commercialize space resources and how to do this on a larger scale, both in terms of volume and of global participation and coordination,' ispace-EUROPE CEO Julien Lamamy told TechCrunch on the eve of the landing attempt. Winning such a contract from NASA was also a first for a European company. But it took some coaxing to get Lammy to brag about the agile team of 50 people from 30 nationalities that made this unique little rover. Techcrunch event Save now through June 4 for TechCrunch Sessions: AI Save $300 on your ticket to TC Sessions: AI—and get 50% off a second. Hear from leaders at OpenAI, Anthropic, Khosla Ventures, and more during a full day of expert insights, hands-on workshops, and high-impact networking. These low-rate deals disappear when the doors open on June 5. Exhibit at TechCrunch Sessions: AI Secure your spot at TC Sessions: AI and show 1,200+ decision-makers what you've built — without the big spend. Available through May 9 or while tables last. Berkeley, CA | REGISTER NOW Despite a resume that includes time at the NASA Jet Propulsion Laboratory and MIT, Lamamy is not one to boast. In our conversation, he admitted he had to 'channel his inner American' to explain his team's achievements. But that's also because ispace is willfully collaborative. For instance, the lightweight scoop that was meant to collect regolith for NASA was made by Epiroc, a mining equipment provider out of Sweden. 'We could have done this ourselves. Instead, we saw the opportunity to engage a terrestrial industry to think about space,' Lamamy said. 'The more people participate, the better.' More people are participating in Luxembourg's space ecosystem, too. The Luxembourg Space Agency (LSA) was established in 2018, and the country actively supports the sector, which has gone from niche to mainstream since the Space Resources Law was adopted. 'Even better than that, there are many companies now established downstream of ispace in the value chain,' Lamamy said. He cited the example of Magna Petra, a startup partnering with ispace on ​​mining Helium-3, a rarefied resource, from the lunar surface. 'Our ambition is to develop a space sector that is highly integrated with our industries on earth and opens up new market opportunities, both in space and on Earth,' Luxembourg's Minister of the Economy, SMEs, Energy and Tourism, Lex Delles, said in a comment when ispace-EUROPE announced the completion of its rover. That ambition is being fueled by money. Tenacious was developed with co-funding from the LSA through an ESA contract with the Luxembourg National Space Program, LuxIMPULSE. Tax incentives or direct aids are available both for startups and for multinational companies, according to research from Deloitte on Luxembourg's space industry. An unusual payload Image Credits:ispace Tenacious was designed to be both small and light, weighing about five kilograms — half the weight of NASA's Sojourner Mars rover. By selecting mass-efficient and power-efficient components, Lamamy explained, his team was able to build a very small system that is cheaper to manufacture and to send to the Moon. This made its payload inherently limited, but designed to reach up to one kilogram. As part of the Resilience mission, Tenacious' payload included the scoop required for the NASA mission, and perhaps unexpectedly, a miniature red house. Known as The Moonhouse, this small sculpture of a Swedish cottage was supposed to symbolically become the first house on the Moon, a project that artist Mikael Genberg has been pursuing since 1999. 'It's not about science or politics, it's about reminding us of what we all share — our humanity, our imagination, and our longing for home. A red house gazing back at 'The Pale Blue Dot', as Carl Sagan once described our fragile planet,' The Moonhouse's site stated. Lamamy's team had prepared to be in charge of successfully dropping and photographing The Moonhouse in a good spot, and took the role seriously. As part of the rover testing it conducted on Earth, both on its testing site in Luxembourg and in several European locations including Spain's Canary Islands, the operators had rehearsed the procedure several times. Although poetic, this may have seemed less of a priority than NASA, but not to Lamamy. 'That's an interesting paradigm shift; yes, we're going to the Moon to improve our knowledge of the Moon from a scientific and commercial perspective, but we are also there to open access to artists, entrepreneurs, educators, and that's also a very exciting element to the mission.' Unfortunately, this will now likely have to wait.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store